Oncolytic Virus Cancer Therapy Market Set for Rapid Growth Through 2036

The oncolytic virus cancer therapy market is expected to expand rapidly during 2026–2036, supported by increasing investments in next-generation cancer treatments, advances in viral engineering, and growing clinical development across multiple tumor types. Oncolytic viruses are designed to selectively infect and destroy cancer cells while stimulating broader antitumor immune responses, creating opportunities for innovative approaches in oncology.

DelveInsight’s Oncolytic Virus Cancer Therapy Market Size, Target Population, Competitive Landscape & Market Forecast provides an assessment of the market across the 7MM, comprising the United States, EU4, the United Kingdom, and Japan. The analysis covers historical and forecasted market trends from 2022 to 2036, along with patient populations, emerging therapies, competitive dynamics, and market opportunities.

To know more about oncolytic virus therapies developers companies, visit @ Oncolytic Virus Landscape - https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Oncolytic Virus Cancer Therapy Market Overview and Growth Outlook

The oncolytic virus cancer therapy market was valued at approximately USD 177 million in the 7MM in 2025. The United States represented the largest share of the market during the same year compared with the EU4, the United Kingdom, and Japan.

The market encompasses a broad range of cancer indications, including melanoma, biliary tract cancer, head and neck cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), hepatocellular carcinoma, breast cancer, prostate cancer, brain cancer, bladder cancer, ovarian cancer, and other malignancies.

Oncolytic virus therapies are particularly being investigated for patients with relapsed or refractory disease. Their ability to combine direct tumor-cell destruction with immune stimulation has generated considerable interest among researchers and developers seeking new treatment approaches for advanced cancers.

Rising Adoption of Novel Cancer Immunotherapies

The increasing adoption of immuno-oncology strategies is one of the major factors supporting the growth of the oncolytic virus cancer therapy market. Unlike conventional treatments that primarily target cancer cells through specific cytotoxic mechanisms, oncolytic viruses can potentially create a localized immune response within tumors.

These therapies may selectively infect malignant cells and cause tumor-cell destruction while releasing tumor-associated antigens that can stimulate immune activity. Certain engineered viruses are additionally designed to deliver therapeutic genes or modify the tumor microenvironment, potentially improving immune recognition and treatment effectiveness.

The expanding focus on personalized and targeted cancer treatments is therefore contributing to increased research into oncolytic virus-based therapeutic platforms.

Advances in Viral Engineering and Clinical Development

Technological progress in genetic engineering has enabled researchers to modify viral platforms to improve tumor selectivity, immune activation, and therapeutic payload delivery. Current clinical development includes adenoviruses, herpes simplex viruses, vaccinia viruses, reoviruses, measles viruses, Newcastle disease viruses, picornaviruses, Maraba viruses, vesicular stomatitis viruses, and other platforms.

The clinical pipeline includes candidates such as Cretostimogene grenadenorepvec, CAN-2409, AdAPT-001, LOAd703, RP1, RP2, VG 161, BS001, Olvi-Vec, CF33, BT-001, TG6050, and Pelareorep.

Increasing clinical trial activity across melanoma, bladder cancer, glioblastoma, ovarian cancer, pancreatic cancer, biliary tract cancer, and other solid tumors is expected to strengthen the commercial potential of this therapeutic class.

Discover real-time oncolytic virus analysis @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Competitive Landscape of Oncolytic Virus Cancer Therapy

The competitive landscape is characterized by multiple biotechnology and pharmaceutical companies advancing investigational therapies across different cancer indications. Key developers include CG Oncology, Candel Therapeutics, EpicentRx, Lokon Pharma, Replimune, Virogin Biotech, Binhui Bio, Genelux, Imugene, BioInvent, Transgene, and Oncolytics Biotech, among others.

Genelux’s Olvi-Vec is a genetically modified vaccinia virus being investigated across several cancer types. Its development strategy focuses on direct tumor-cell destruction, activation of tumor-specific immune responses, and modification of the tumor microenvironment.

CG Oncology’s cretostimogene grenadenorepvec is an investigational intravesical oncolytic immunotherapy being studied in non-muscle-invasive bladder cancer. The candidate has been evaluated in Phase III programs targeting different patient populations with bladder cancer.

Another example is BT-001, developed through collaboration between BioInvent and Transgene. The engineered oncolytic virus is designed to deliver an anti-CTLA-4 antibody directly within tumors and is being investigated in combination with pembrolizumab.

Recent Developments Shaping the Market

The oncolytic virus cancer therapy landscape has witnessed several notable developments in 2026. In August 2026, Replimune announced that the U.S. FDA granted accelerated approval to TUDRIQEVTM (vusolimogene oderparepvec-wtpg), formerly RP1, in combination with nivolumab for certain adults with unresectable advanced cutaneous melanoma following progression after an anti-PD-1-based regimen.

In July 2026, UroGen Pharma announced FDA clearance of its IND application for UGN-501, supporting plans for a Phase I clinical trial in non-muscle-invasive bladder cancer.